Transferrin receptor-mediated endocytosis: A useful target for cancer therapy

Journal of Membrane Biology

Volumn 247, Issue 4, 2014, Pages 291-307

  Tortorella, Stephanie ^a,b   Karagiannis, Tom C ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cancer therapy; Immunoconjugate; Immunotargeting; Transferrin; Transferrin receptor

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 84898871917     PISSN: 00222631     EISSN: 14321424     Source Type: Journal    
DOI: 10.1007/s00232-014-9637-0     Document Type: Review

References (143)

1. Aisen P, Leibman A, Zweier J (1978) Stoichiometric and site characteristics of the binding of iron to human transferrin. J Biol Chem 253(6):1930-1937
2. Batra JK, Jinno Y, Chaudhary VK, Kondo T, Willingham MC, FitzGerald DJ, Pastan I (1989) Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc Natl Acad Sci USA 86(21):8545-8549
3. Batra JK, Fitzgerald DJ, Chaudhary VK, Pastan I (1991) Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cell Biol 11(4):2200-2205
4. Bejaoui N, Page M, Noel C (1991) Cytotoxicity of transferrin-daunorubicin conjugates on small cell carcinoma of the lung (SCCL) cell line NCI-H69. Anticancer Res 11(6):2211-2213
5. Berczi A, Barabas K, Sizensky JA, Faulk WP (1993) Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells. Arch Biochem Biophys 300(1):356-363
6. Bergamaschi G, Cazzola M, Dezza L, Savino E, Consonni L, Lappi D (1988) Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). Br J Haematol 68(3):379-384
7. Bleil JD, Bretscher MS (1982) Transferrin receptor and its recycling in HeLa cells. EMBO J 1(3):351-355
8. Brandsma M, Jevnikar A, Ma S (2011) Recombinant human transferrin: beyond iron binding and transport. Biotechnol Adv 29(2):230-238
9. Bridges KR, Cudkowicz A (1984) Effect of iron chelators on the transferrin receptor in K562 cells. J Biol Chem 259(21):12970-12977
10. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54(5):631-651
11. Burdo JR, Antonetti DA, Wolpert EB, Connor JR (2003) Mechanisms and regulation of transferrin and iron transport in a model blood-brain barrier system. Neuroscience 121(4):883-890
12. Calzolari A, Deaglio S, Sposi N, Petrucci E, Morsilli O, Gabbianelli M, Malavasi F, Peschle C, Testa U (2004) Transferrin receptor 2 protein is not expressed in normal erythroid cells. Biochem J 381(3):629-634
13. Calzolari A, Oliviero I, Deaglio S, Mariani G, Biffoni M, Sposi N, Malavasi F, Peschle C, Testa U (2007) Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis 39(1):82-91
14. Calzolari A, Larocca L, Deaglio S, Finisguerra V, Boe A, Raggi C, Ricci Vitani L, Pierconti F, Malavasi F, De Maria R, Testa U, Pallini R (2010) Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl Oncol 3(2):123-134
15. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ (2013) Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. doi: 10.1002/med.21280
16. Chang J, Paillard A, Passirani C, Morille M, Benoit J-P, Betbeder D, Garcion E (2012) Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res 29(6):1495-1505
17. Chiu S-J, Liu S, Perrotti D, Marcucci G, Lee R (2006) Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 112(2):199-207
18. Choudhary S, Mathew M, Verma RS (2011) Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16(11-12):495-503
19. Ciechanover A, Schwartz AL, Dautry-Varsat A, Lodish HF (1983) Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J Biol Chem 258(16):9681-9689
20. Cimini A, Mei S, Benedetti E, Laurenti G, Koutris I, Cinque B, Cifone MG, Galzio R, Pitari G, Di Leandro L, Giansanti F, Lombardi A, Fabbrini MS, Ippoliti R (2012) Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines. J Cell Physiol 227(3):939-951
21. Conner S, Schmid S (2003) Regulated portals of entry into the cell. Nature 422(6927):37-44
22. Daniels T, Delgado T, Rodriguez J, Helguera G, Penichet M (2006a) The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121(2):144-158
23. Daniels TR, Delgado T, Helguera G, Penichet ML (2006b) The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clinical Immunology 121(2):159-176. doi: 10.1016/j.clim.2006.06.006
24. Daniels TR, Ng PP, Delgado T, Lynch MR, Schiller G, Helguera G, Penichet ML (2007) Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther 6(11):2995-3008
25. Das Gupta A, Shah VI (1990) Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and Non-Hodgkin's lymphoma. Hematol Pathol 4(1):37-41
26. Dautry Varsat A, Ciechanover A, Lodish HF (1983) pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci USA 80(8):2258-2262
27. Deaglio S, Capobianco A, CalI A, Bellora F, Alberti F, Righi L, Sapino A, Camaschella C, Malavasi F (2002) Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum. Blood 100(10):3782-3789. doi: 10.1182/blood-2002-01-0076
28. Descamps L, Dehouck MP, Torpier G, Cecchelli R (1996) Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am J Physiol 270(4):H1149-H1158
29. Dufes C, Al Robaian M, Somani S (2013) Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Therapeutic delivery 4(5):629-640
30. El Hage Chahine J-M, Hémadi M, Ha-Duong N-T (1820) Hémadi M, Ha-Duong NT (2012) Uptake and release of metal ions by transferrin and interaction with receptor 1. Biochimica et Biophysica Acta (BBA) 3:334-347. doi: 10.1016/j.bbagen.2011.07.008 General Subjects
31. Elliott R, Head J (2006) Complete resolution of malignant ascites in stage IV breast cancer by peritoneal drainage and innovative chemoimmunotherapy: a case report. Cancer Biother Radiopharm 21(2):138-145
32. Faulk WP, Hsi BL, Stevens PJ (1980) Transferrin and transferrin receptors in carcinoma of the breast. Lancet (Lond) 2(8191):390-392
33. Faulk WP, Taylor CG, Yeh CJ, McIntyre JA (1990) Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Mol Biother 2(1):57-60
34. Faulk WP, Barabas K, Sun IL, Crane FL (1991) Transferrin-adriamycin conjugates which inhibit tumor cell proliferation without interaction with DNA inhibit plasma membrane oxidoreductase and proton release in K562 cells. Biochem Int 25(5):815-822
35. Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328-335. doi: 10.1016/j.bbrc.2005.05.132
36. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM (1991) Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 88(11):4771-4775
37. Galbraith GM, Galbraith RM, Temple A, Faulk WP (1980) Demonstration of transferrin receptors on human placental trophoblast. Blood 55(2):240-242
38. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY (1983) Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 36(5):539-545
39. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2(1):48-58
40. Griffin TW, Stocl M, Collins J, Fernandes J, Maher VE (1992) Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies. J Immunother 11(1):12-18
41. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF (1983) Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet (Lond) 1(8323):498-501
42. Hamilton TA, Wada HG, Sussman HH (1979) Identification of transferrin receptors on the surface of human cultured cells. Proceedings of the National Academy of Sciences of the United States of America. Proc Natl Acad Sci USA 76(12):6406-6410
43. Hammarström ML, Axelsson B, Ivansen M, Hammarström S, Perlmann P (1982) Transferrin receptors on mitogen-stimulated human thymus-derived lymphocytes. Scand J Immunol 16(4):355-360
44. Head JF, Wang F, Elliott RL (1997) Antineoplastic drugs that interfere with iron metabolism in cancer cells. Adv Enzyme Regul 37:147-169
45. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027. doi: 10.1200/jco.2005.06.081
46. Hopkins CR, Trowbridge IS (1983) Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Biol 97(2):508-521
47. Hoshino T, Misaki M, Yamamoto M, Shimizu H, Ogawa Y, Toguchi H (1995) In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. J Pharm Sci 84(2):216-221
48. Huang Y, He L, Liu W, Fan C, Zheng W, Wong Y-S, Chen T (2013) Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials 34(29):7106-7116. doi: 10.1016/j.biomaterials.2013. 04.067
49. Huebers HA, Finch CA (1987) The physiology of transferrin and transferrin receptors. Physiol Rev 67(2):520-582
50. Ippoliti R, Lendaro E, D'Agostino I, Fiani ML, Guidarini D, Vestri S, Benedetti PA, Brunori M (1995) A chimeric saporin-transferrin conjugate compared to ricin toxin: role of the carrier in intracellular transport and toxicity. FASEB J 9(12):1220-1225
51. Jain RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46(1-3):149-168
52. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY (1984) Transferrin receptor on endothelium of brain capillaries. Nature 312(5990):162-163
53. Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY (2007) Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug Chem 18(1):41-49
54. Jiang W, KimBetty YS, Rutka JT, ChanWarren CW (2008) Nanoparticle- mediated cellular response is size-dependent. Nat Nano 3(3):145-150. http://www.nature.com/nnano/journal/v3/n3/suppinfo/nnano.2008.30-S1.html
55. Jin M, Snider MD (1993) Role of microtubules in transferrin receptor transport from the cell surface to endosomes and the Golgi complex. J Biol Chem 268(24):18390-18397
56. Karagiannis T, Lobachevsky P, Martin R (2006a) DNA targeted UVA photosensitization: characterization of an extremely photopotent iodinated minor groove binding DNA ligand. J Photochem Photobiol B 83(3):195-204
57. Karagiannis TC, Lobachevsky PN, Leung BK, White JM, Martin RF (2006b) Receptor-mediated DNA-targeted photoimmunotherapy. Cancer Res 66(21):10548-10552
58. Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW, Koeffler HP (2000) Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J Biol Chem 275(22):16618-16625
59. Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405(6785):421-424
60. Kim TH, Jo YG, Jiang HH, Lim SM, Youn YS, Lee S, Chen X, Byun Y, Lee KC (2012) PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Control Release 162(2):422-428. doi: 10.1016/j.jconrel.2012.07.021
61. Kim S, Saha K, Kim C, Rotello V (2013) The role of surface functionality in determining nanoparticle cytotoxicity. Acc Chem Res 46(3):681-691
62. Klausner RD, Ashwell G, van Renswoude J, Harford JB, Bridges KR (1983a) Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc Natl Acad Sci USA 80(8):2263-2266
63. Klausner RD, Van Renswoude J, Ashwell G, Kempf C, Schechter AN, Dean A, Bridges KR (1983b) Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem 258(8):4715-4724
64. Kondo K, Noguchi M, Mukai K, Matsuno Y, Sato Y, Shimosato Y, Monden Y (1990) Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 97(6):1367-1371
65. Koppu S, Oh YJ, Edrada-Ebel R, Blatchford DR, Tetley L, Tate RJ, Dufès C (2010) Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Control Release 143(2):215-221. doi: 10.1016/j.jconrel.2009.11.015
66. Kratz F, Beyer U, Roth T, Tarasova N, Collery P, Lechenault F, Cazabat A, Schumacher P, Unger C, Falken U (1998) Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J Pharm Sci 87(3):338-346
67. Kratz F, Roth T, Fichiner I, Schumacher P, Fiebig HH, Unger C (2000) In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model. J Drug Target 8(5):305-318
68. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20(8):716-731
69. Lakadamyali M, Rust M, Zhuang X (2006) Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell 124(5):997-1009
70. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH (1994) Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 80(3):520-526
71. Laske DW, Muraszko KM, Oldfield EH, DeVroom HL, Sung C, Dedrick RL, Simon TR, Colandrea J, Copeland C, Katz D, Greenfield L, Groves ES, Houston LL, Youle RJ (1997a) Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 41(5):1039-1049
72. Laske DW, Youle RJ, Oldfield EH (1997b) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3(12):1362-1368
73. Lemieux P, Page M (1994) Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate. Anticancer Res 14(2A):397-403
74. Liu G, Mao J, Jiang Z, Sun T, Hu Y, Zhang C, Dong J, Huang Q, Lan Q (2013) Transferrin-modified doxorubicin-loaded biodegradable nanoparticles exhibit enhanced efficacy in treating brain glioma-bearing rats. Cancer Biother Radiopharma 28(9):691-696
75. Lubgan D, Jozwiak Z, Grabenbauer GG, Distel LV (2009) Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells. Cell Mol Biol Lett 14(1):113-127
76. Luck A, Mason A (2012) Transferrin-mediated cellular iron delivery. Curr Top Membr 69:3-35
77. Madhumathi J, Verma RS (2012) Therapeutic targets and recent advances in protein immunotoxins. Curr Opin Microbiol 15(3):300-309. doi: 10.1016/j.mib.2012.05.006
78. Martell LA, Agrawal A, Ross DA, Muraszko KM (1993) Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53(6):1348-1353
79. Martin RF, Murray V, D'Cunha G, Pardee M, Kampouris E, Haigh A, Kelly DP, Hodgson GS (1990) Radiation sensitization by an iodine-labelled DNA ligand. Int J Radiat Biol 57(5):939-946
80. Matsui T, Fukuda M (2011) Small GTPase Rab12 regulates transferrin receptor degradation: implications for a novel membrane trafficking pathway from recycling endosomes to lysosomes. Cell Logist 1(4):155-158
81. Matsui T, Itoh T, Fukuda M (2011) Small GTPase Rab12 regulates constitutive degradation of transferrin receptor. Traffic 12(10):1432-1443
82. Mattia E, Rao K, Shapiro DS, Sussman HH, Klausner RD (1984) Biosynthetic regulation of the human transferrin receptor by desferrioxamine in K562 cells. J Biol Chem 259(5):2689-2692
83. Mayle K, Le A, Kamei D (2012) The intracellular trafficking pathway of transferrin. Biochimica et biophysica acta 1820(3):264-281
84. McCaffrey MW, Bielli A, Cantalupo G, Mora S, Roberti V, Santillo M, Drummond F, Bucci C (2001) Rab4 affects both recycling and degradative endosomal trafficking. FEBS Lett 495(1-2):21-30. doi: 10.1016/S0014-5793(01)02359-6
85. McClelland A, Kühn LC, Ruddle FH (1984) The human transferrin receptor gene: genomic organization, and the complete primary structure of the receptor deduced from a cDNA sequence. Cell 39(2):267-274
86. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19(56):6550-6565
87. Mendelsohn J, Trowbridge I, Castagnola J (1983) Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor. Blood 62(4):821-826
88. Mout R, Moyano D, Rana S, Rotello V (2012) Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev 41(7):2539-2544
89. Munns J, Yaxley J, Coomer J, Lavin MF, Gardiner RA, Watters D (1998) Evaluation of the potential of transferrin-adriamycin conjugates in the treatment of bladder cancer. Br J Urol 82(2):284-289
90. Nam J-P, Park S-C, Kim T-H, Jang J-Y, Choi C, Jang M-K, Nah J-W (2013) Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery. Int J Pharm 457(1):124-135
91. Neckers LM, Trepel JB (1986) Transferrin receptor expression and the control of cell growth. Cancer Invest 4(5):461-470
92. O'Keefe DO, Draper RK (1985) Characterization of a transferrin-diphtheria toxin conjugate. J Biol Chem 260(2):932-937
93. Panaccio M, Zalcberg JR, Thompson CH, Leyden MJ, Sullivan JR, Lichtenstein M, McKenzie IF (1987) Heterogeneity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours in vivo. Immunol Cell Biol 65(6):461-472
94. Paris-Robidas S, Emond V, Tremblay C, Soulet D, Calon F (2011) In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol Pharmacol 80(1):32-39. doi: 10.1124/mol.111.071027
95. Pirker R, FitzGerald DJP, Hamilton TC, Ozols RF, Willingham MC, Pastan I (1985) Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res 45(2):751-757
96. Pirker R, FitzGerald DJP, Willingham MC, Pastan I (1988) Enhancement of the activity of immunotoxins made with either ricin a chain or pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. Cancer Res 48(14):3919-3923
97. Prior R, Reifenberger G, Wechsler W (1990) Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Archiv 416(6):491-496
98. Prutki M, Poljak Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N (2006) Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett 238(2):188-196
99. Raso V, Basala M (1984) A highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cells. J Biol Chem 259(2):1143-1149
100. Recht L, Torres CO, Smith TW, Raso V, Griffin TW (1990) Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 72(6):941-945. doi: 10.3171/jns.1990.72.6.0941
101. Richardson DR, Ponka P (1997) The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331(1):1-40
102. Rouault T, Rao K, Harford J, Mattia E, Klausner RD (1985) Hemin, chelatable iron, and the regulation of transferrin receptor biosynthesis. J Biol Chem 260(27):14862-14866
103. Rutledge EA, Mikoryak CA, Draper RK (1991) Turnover of the transferrin receptor is not influenced by removing most of the extracellular domain. J Biol Chem 266(31):21125-21130
104. Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J (2004) Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 40(9):1418-1422
105. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2(5):373-383. doi: 10.1021/mp050032z
106. Sahoo SK, Ma W, Labhasetwar V (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112(2):335-340. doi: 10.1002/ijc.20405
107. Schneider C, Sutherland R, Newman R, Greaves M (1982) Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9. J Biol Chem 257(14):8516-8522
108. Schneider C, Owen MJ, Banville D, Williams JG (1984) Primary structure of human transferrin receptor deduced from the mRNA sequence. Nature 311(5987):675-678
109. Schulman HM, Wilczynska A, Ponka P (1981) Transferrin and iron uptake by human lymphoblastoid and K-562 cells. Biochem Biophys Res Commun 100(4):1523-1530
110. Scott CF Jr, Goldmacher VS, Lambert JM, Jackson JV, McIntyre GD (1987) An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors. J Natl Cancer Inst 79(5):1163-1172
111. Seymour GJ, Walsh MD, Lavin MF, Strutton G, Gardiner RA (1987) Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 15(6):341-344
112. Shapira A, Benhar I (2010) Toxin-based therapeutic approaches. Toxins 2(11):2519-2583
113. Shinohara H, Fan D, Ozawa S, Yano S, Van Arsdell M, Viner JL, Beers R, Pastan I, Fidler IJ (2000) Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Int J Oncol 17(4):643-651
114. Sieff C, Bicknell D, Caine G, Robinson J, Lam G, Greaves MF (1982) Changes in cell surface antigen expression during hemopoietic differentiation. Blood 60(3):703-713
115. Singh M (1999) Transferrin As A targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 5(6):443-451
116. Singh M, Atwal H, Micetich R (1998) Transferrin directed delivery of adriamycin to human cells. Anticancer Res 18(3A):1423-1427
117. Singh M, Mugler K, Hailoo D, Burke S, Nemesure B, Torkko K, Shroyer K (2011) Differential expression of transferrin receptor (TfR) in a spectrum of normal to malignant breast tissues: implications for in situ and invasive carcinoma. Appl Immunohistochem Mol Morphol 19(5):417-423
118. Speth PAJ, Hoesel QGCM, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin-Pharmacokinet 15(1):15-31. doi: 10.2165/00003088-198815010- 00002
119. Steere A, Byrne S, Chasteen ND (1820) Mason A (2012) Kinetics of iron release from transferrin bound to the transferrin receptor at endosomal pH. Biochim Biophys Acta 3:326-333
120. Stein BS, Sussman HH (1986) Demonstration of two distinct transferrin receptor recycling pathways and transferrin-independent receptor internalization in K562 cells. J Biol Chem 261(22):10319-10331
121. Sun IL, Sun EE, Crane FL, Morre DJ, Faulk WP (1992) Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates. Biochim Biophys Acta 23(1):84-88
122. Sutherland R, Delia D, Schneider C, Newman R, Kemshead J, Greaves M (1981) Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc Natl Acad Sci 78(7):4515-4519
123. Szwed M, Matusiak A, Laroche-Clary A, Robert J, Marszalek I, Jozwiak Z (2013) Transferrin as a drug carrier: cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Toxicol Vitro. doi: 10.1016/j.tiv.2013.09.013
124. Taetle R, Honeysett JM, Trowbridge I (1983) Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells. Int J Cancer 32(3):343-349
125. Taetle R, Castagnola J, Mendelsohn J (1986) Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res 46(4):1759-1763
126. Trinder D, Baker E (2003) Transferrin receptor 2: a new molecule in iron metabolism. Int J Biochem Cell Biol 35(3):292-296
127. Trowbridge IS, Domingo DL (1981) Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 294(5837):171-173
128. Trowbridge IS, Lopez F (1982) Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci USA 79(4):1175-1179
129. Trowbridge IS, Omary MB (1981) Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci 78(5):3039-3043
130. Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharma Biopharma 71(2):251-256. doi: 10.1016/j.ejpb.2008.08.021
131. van der Meel R, Vehmeijer LJC, Kok RJ, Storm G, van Gaal EVB (2013) Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 65(10):1284-1298. doi: 10.1016/j.addr.2013. 08.012
132. Wang F, Jiang X, Yang DC, Elliott RL, Head JF (2000) Doxorubicin-gallium- transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res 20(2A):799-808
133. Ward JH, Jordan I, Kushner JP, Kaplan J (1984) Heme regulation of HeLa cell transferrin receptor number. J Biol Chem 259(21):13235-13240
134. Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) therapy of malignant gliomas. J Neurooncol 65(1):3-13
135. Whitesides GM (2003) The 'right' size in nanobiotechnology. Nat Biotechnol 21(10):1161-1165
136. Woith W, Nüsslein I, Antoni C, Dejica DI, Winkler TH, Herrmann M, Pirner K, Kalden JR, Manger B (1993) A soluble form of the human transferrin receptor is released by activated lymphocytes in vitro. Clin Exp Immunol 92(3):537-542
137. Wrba F, Ritzinger E, Reiner A, Holzner JH (1986) Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. An immunohistochemical study. Virchows Archiv A 410(1):69-73
138. Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee R (2007) Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharma Sci 10(3):350-357
139. Wu L, Wu J, Zhou Y, Tang X, Du Y, Hu Y (2012) Enhanced antitumor efficacy of cisplatin by tirapazamine-transferrin conjugate. Int J Pharm 431(1-2):190-196. doi: 10.1016/j.ijpharm.2012.04.032
140. Yashunsky V, Shimron S, Lirtsman V, Weiss A, Melamed Book N, Golosovsky M, Davidov D, Aroeti B (2009) Real-time monitoring of transferrin-induced endocytic vesicle formation by mid-infrared surface plasmon resonance. Biophys J 97(4):1003-1012
141. Yeh CJ, Taylor CG, Faulk WP (1984) Transferrin binding by peripheral blood mononuclear cells in human lymphomas, myelomas and leukemias. Vox Sang 46(4):217-223
142. Yoon D, Chu DSH, Ng C, Pham E, Mason A, Hudson D, Smith V, MacGillivray RTA, Kamei D (2009) Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J Control Release 133(3):178-184
143. Zerial M, Melancon P, Schneider C, Garoff H (1986) The transmembrane segment of the human transferrin receptor functions as a signal peptide. EMBO J 5(7):1543-1550